Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
Rev. Soc. Bras. Med. Trop
; Rev. Soc. Bras. Med. Trop;53: e20190594, 2020. tab, graf
Article
em En
| SES-SP, ColecionaSUS, LILACS
| ID: biblio-1136866
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract INTRODUCTION We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTS:
Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option.CONCLUSIONS:
The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Antivirais
/
Hepacivirus
/
Hepatite C Crônica
/
Quimioterapia Combinada
Tipo de estudo:
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
Limite:
Humans
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Assunto da revista:
MEDICINA TROPICAL
Ano de publicação:
2020
Tipo de documento:
Article